Modern Management of Acute Myocardial Infarction

Current Problems in Cardiology

Volumn 37, Issue 7, 2012, Pages 237-310

  Welch, Terrence D ^a   Yang, Eric H ^a   Reeder, Guy S ^a   Gersh, Bernard J ^a  

^a NONE

Author keywords

[No Author keywords available]

Indexed keywords

ABCIXIMAB; ACETYLSALICYLIC ACID; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTITHROMBOCYTIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; BLOOD CLOTTING FACTOR 10A INHIBITOR; CLOPIDOGREL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; ENOXAPARIN; FIBRINOGEN RECEPTOR ANTAGONIST; FONDAPARINUX; GLYCERYL TRINITRATE; HEPARIN; HEPARIN DERIVATIVE; HIRULOG; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; LOW MOLECULAR WEIGHT HEPARIN; METOPROLOL; MORPHINE; NITRATE; PLACEBO; PRASUGREL; PURINERGIC RECEPTOR BLOCKING AGENT; REVIPARIN; STREPTOKINASE; THIENOPYRIDINE DERIVATIVE; THROMBIN INHIBITOR; TICAGRELOR; TIROFIBAN; UNINDEXED DRUG;

ACUTE CORONARY SYNDROME; ACUTE HEART INFARCTION; ADJUVANT THERAPY; ANTICOAGULANT THERAPY; ARTICLE; BLEEDING; BLOOD CLOT LYSIS; BRADYCARDIA; BRAIN HEMORRHAGE; CARDIOGENIC SHOCK; CENTRAL VENOUS PRESSURE; CLINICAL FEATURE; COMBINATION CHEMOTHERAPY; COMPLETE HEART BLOCK; CONSERVATIVE TREATMENT; CONTINUOUS INFUSION; CORONARY ARTERY THROMBOSIS; CORONARY STENT; DEFIBRILLATION; DIAPHORESIS; DIFFERENTIAL DIAGNOSIS; DISEASE CLASSIFICATION; DISEASE MARKER; DRUG DOSE COMPARISON; DRUG DOSE INCREASE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG SAFETY; DYSPNEA; EARLY DIAGNOSIS; EARLY INTERVENTION; ELECTROCARDIOGRAPHY; FIBRINOLYTIC THERAPY; HEART ATRIUM FIBRILLATION; HEART ATRIUM FLUTTER; HEART BUNDLE BRANCH BLOCK; HEART INJURY; HEART LEFT BUNDLE BRANCH BLOCK; HEART LEFT VENTRICLE FAILURE; HEART MUSCLE CONDUCTION DISTURBANCE; HEART MUSCLE REPERFUSION; HEART REHABILITATION; HEART RUPTURE; HEART VENTRICLE TACHYCARDIA; HOSPITAL CARE; HUMAN; INCIDENCE; LIFESTYLE MODIFICATION; LOADING DRUG DOSE; MAINTENANCE THERAPY; MITRAL VALVE REGURGITATION; MORBIDITY; MORTALITY; NAUSEA; NON ST SEGMENT ELEVATION ACUTE CORONARY SYNDROME; OXYGEN THERAPY; PATHOPHYSIOLOGY; PERCUTANEOUS CORONARY INTERVENTION; PERCUTANEOUS THROMBECTOMY; PREVALENCE; RECOMMENDED DRUG DOSE; RISK ASSESSMENT; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SECONDARY PREVENTION; SMOKING CESSATION; ST SEGMENT ELEVATION; ST SEGMENT ELEVATION MYOCARDIAL INFARCTION; SUBSTERNAL PAIN; T WAVE INVERSION; TACHYCARDIA; THROMBOCYTE FUNCTION; TREATMENT CONTRAINDICATION; VASODILATATION; VENTRICULAR FREE WALL RUPTURE;

BIOLOGICAL MARKERS; CARDIOVASCULAR AGENTS; DIAGNOSIS, DIFFERENTIAL; ELECTROCARDIOGRAPHY; HUMANS; MYOCARDIAL INFARCTION; MYOCARDIAL REPERFUSION; RISK ASSESSMENT;

EID: 84861759937     PISSN: 01462806     EISSN: 15356280     Source Type: Journal    
DOI: 10.1016/j.cpcardiol.2012.03.002     Document Type: Article

References (211)

1. Yang E.H., Brilakis E.S., Reeder G.S., et al. Modern management of acute myocardial infarction. Curr Probl Cardiol 2006, 31:769-817.
2. Antman E.M., Anbe D.T., Armstrong P.W., et al. ACC/AHA guidelines for the management of patients with ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (committee to revise the 1999 guidelines for the management of patients with acute myocardial infarction). Circulation 2004, 110:e82-e292.
3. Antman E.M., Hand M., Armstrong P.W., et al. Focused update of the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines: developed in collaboration with the Canadian Cardiovascular Society endorsed by the American Academy of Family Physicians: 2007 Writing Group to review new evidence and update the ACC/AHA 2004 guidelines for the management of patients with ST-Elevation myocardial infarction, writing on behalf of the 2004 Writing Committee. Circulation 2008, 117:296-329.
4. Kushner F.G., Hand M., Smith S.C., et al. Focused updates: ACC/AHA guidelines for the management of patients with ST-Elevation myocardial infarction (updating the 2004 guideline and 2007 focused update) and ACC/AHA/SCAI guidelines on percutaneous coronary intervention (updating the 2005 guideline and 2007 focused update): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2009, 120:2271-2306.
5. Anderson J.L., Adams C.D., Antman E.M., et al. ACC/AHA 2007 guidelines for the management of patients with unstable angina/non ST-elevation myocardial infarction: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the 2002 guidelines for the management of patients with unstable angina/non ST-Elevation myocardial infarction): developed in collaboration with the American College of Emergency Physicians, the society for cardiovascular angiography and interventions, and the society of thoracic surgeons: endorsed by the American Association of Cardiovascular and Pulmonary Rehabilitation and the society for academic emergency medicine. Circulation 2007, 116:e148-e304.
6. Wright R.S., Anderson J.L., Adams C.D., et al. ACCF/AHA Focused update of the guidelines for the management of patients with unstable angina/non-ST-Elevation myocardial infarction (updating the 2007 guideline): a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines. Circulation 2011, 123:2022-2060.
7. Levine G.N., Bates E.R., Blankenship J.C., et al. ACCF/AHA/SCAI guideline for percutaneous coronary intervention A report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines and the Society for Cardiovascular Angiography and Interventions. J Am Coll Cardiol 2011, 58:e44-e122.
8. Roger V.L., Go A.S., Lloyd-Jones D.M., et al. Heart disease and stroke statistics-2011 update: a report from the American Heart Association. Circulation 2011, 123:e18-e209.
9. Yeh R.W., Sidney S., Chandra M., et al. Population trends in the incidence and outcomes of acute myocardial infarction. N Engl J Med 2010, 362:2155-2165.
10. Xavier D., Pais P., Devereaux P.J., et al. Treatment and outcomes of acute coronary syndromes in India (CREATE): a prospective analysis of registry data. Lancet 2008, 371:1435-1442.
11. DeWood M.A., Spores J., Notske R., et al. Prevalence of total coronary occlusion during the early hours of transmural myocardial infarction. N Engl J Med 1980, 303:897-902.
12. DeWood M.A., Stifter W.F., Simpson C.S., et al. Coronary arteriographic findings soon after non-Q-wave myocardial infarction. N Engl J Med 1986, 315:417-423.
13. Stone G.W., Maehara A., Lansky A.J., et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011, 364:226-235.
14. Reynolds H.R., Hochman J.S. Cardiogenic shock: current concepts and improving outcomes. Circulation 2008, 117:686-697.
15. Nestler D.M., White R.D., Rihal C.S., et al. Impact of prehospital electrocardiogram protocol and immediate catheterization team activation for patients with ST-Elevation-Myocardial infarction. Circ Cardiovasc Qual Outcomes 2011, 4:640-646.
16. Wagner G.S., Macfarlane P., Wellens H., et al. AHA/ACCF/HRS recommendations for the standardization and interpretation of the electrocardiogram: part VI: Acute ischemia/infarction: a scientific statement from the American Heart Association Electrocardiography and Arrhythmias Committee, Council on Clinical Cardiology; the American College of Cardiology Foundation; and the Heart Rhythm Society: endorsed by the International Society for Computerized Electrocardiology. Circulation 2009, 119:e262-e270.
17. Sgarbossa E.B., Pinski S.L., Barbagelata A., et al. Electrocardiographic diagnosis of evolving acute myocardial infarction in the presence of left bundle-branch block. GUSTO-1 (global utilization of streptokinase and tissue plasminogen activator for occluded coronary arteries) investigators. N Engl J Med 1996, 334:481-487.
18. Prasad A., Stone G.W., Holmes D.R., et al. Reperfusion injury, microvascular dysfunction, and cardioprotection: the "dark side" of reperfusion. Circulation 2009, 120:2105-2112.
19. Thygesen K., Alpert J.S., White H.D., et al. Universal definition of myocardial infarction. Circulation 2007, 116:2634-2653.
20. Antman E.M., Tanasijevic M.J., Thompson B., et al. Cardiac-specific troponin I levels to predict the risk of mortality in patients with acute coronary syndromes. N Engl J Med 1996, 335:1342-1349.
21. Ohman E.M., Armstrong P.W., Christenson R.H., et al. Cardiac troponin T levels for risk stratification in acute myocardial ischemia. GUSTO IIA investigators. N Engl J Med 1996, 335:1333-1341.
22. Jaffe A.S., Babuin L., Apple F.S. Biomarkers in acute cardiac disease: the present and the future. J Am Coll Cardiol 2006, 48:1-11.
23. Keller T., Zeller T., Ojeda F., et al. Serial changes in highly sensitive troponin I assay and early diagnosis of myocardial infarction. JAMA 2011, 306:2684-2693.
24. Killip T., Kimball J.T. Treatment of myocardial infarction in a coronary care unit. A two year experience with 250 patients. Am J Cardiol 1967, 20:457-464.
25. Cabello J.B., Burls A., Emparanza J.I., et al. Oxygen therapy for acute myocardial infarction. Cochrane Database Syst Rev 2010, CD007160.
26. Randomised trial of intravenous streptokinase, oral aspirin, both, or neither among 17,187 cases of suspected acute myocardial infarction: ISIS-2. ISIS-2 (second international study of infarct survival) collaborative group. Lancet 1988, 2:349-360.
27. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction, and stroke in high risk patients. BMJ 2002, 324:71-86. Antithrombotic Trialists' Collaboration.
28. Jugdutt B.I., Warnica J.W. Intravenous nitroglycerin therapy to limit myocardial infarct size, expansion, and complications. Effect of timing, dosage, and infarct location. Circulation 1988, 78:906-919.
29. GISSI-3: effects of lisinopril and transdermal glyceryl trinitrate singly and together on 6-week mortality and ventricular function after acute myocardial infarction. Gruppo Italiano per lo studio della Sopravvivenza nell'infarto Miocardico. Lancet 1994, 343:1115-1122.
30. Anderson J.L., Karagounis L.A., Califf R.M. Metaanalysis of five reported studies on the relation of early coronary patency grades with mortality and outcomes after acute myocardial infarction. Am J Cardiol 1996, 78:1-8.
31. Gersh B.J., Stone G.W., White H.D., et al. Pharmacological facilitation of primary percutaneous coronary intervention for acute myocardial infarction: is the slope of the curve the shape of the future?. JAMA 2005, 293:979-986.
32. Stone G.W., Grines C.L., Cox D.A., et al. Comparison of angioplasty with stenting, with or without abciximab, in acute myocardial infarction. N Engl J Med 2002, 346:957-966.
33. The effects of tissue plasminogen activator, streptokinase, or both on coronary-artery patency, ventricular function, and survival after acute myocardial infarction. The GUSTO Angiographic Investigators. N Engl J Med 1993, 329:1615-1622.
34. Keeley E.C., Boura J.A., Grines C.L. Primary angioplasty versus intravenous thrombolytic therapy for acute myocardial infarction: a quantitative review of 23 randomised trials. Lancet 2003, 361:13-20.
35. Svilaas T., Vlaar P.J., van der Horst I.C., et al. Thrombus aspiration during primary percutaneous coronary intervention. N Engl J Med 2008, 358:557-567.
36. Grines C.L., Cox D.A., Stone G.W., et al. Coronary angioplasty with or without stent implantation for acute myocardial infarction. Stent primary angioplasty in myocardial infarction study group. N Engl J Med 1999, 341:1949-1956.
37. Stone G.W., Lansky A.J., Pocock S.J., et al. Paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction. N Engl J Med 2009, 360:1946-1959.
38. Brar S.S., Leon M.B., Stone G.W., et al. Use of drug-eluting stents in acute myocardial infarction: a systematic review and meta-analysis. J Am Coll Cardiol 2009, 53:1677-1689.
39. Widimský P., Budesínský T., Vorác D., et al. Long distance transport for primary angioplasty vs immediate thrombolysis in acute myocardial infarction. Final results of the randomized national multicentre trial-PRAGUE-2. Eur Heart J 2003, 24:94-104.
40. Grines C.L., Westerhausen D.R., Grines L.L., et al. A randomized trial of transfer for primary angioplasty versus on-site thrombolysis in patients with high-risk myocardial infarction: the air primary angioplasty in myocardial infarction study. J Am Coll Cardiol 2002, 39:1713-1719.
41. Andersen H.R., Nielsen T.T., Rasmussen K., et al. A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 2003, 349:733-742.
42. Pinto D.S., Kirtane A.J., Nallamothu B.K., et al. Hospital delays in reperfusion for ST-elevation myocardial infarction: implications when selecting a reperfusion strategy. Circulation 2006, 114:2019-2025.
43. Terkelsen C.J., Sorensen J.T., Maeng M., et al. System delay and mortality among patients with STEMI treated with primary percutaneous coronary intervention. JAMA 2010, 304:763-771.
44. Terkelsen C.J., Jensen L.O., Tilsted H.H., et al. Health care system delay and heart failure in patients with ST-segment elevation myocardial infarction treated with primary percutaneous coronary intervention: follow-up of population-based medical registry data. Ann Intern Med 2011, 155:361-367.
45. Jollis J.G., Roettig M.L., Aluko A.O., et al. Implementation of a statewide system for coronary reperfusion for ST-segment elevation myocardial infarction. JAMA 2007, 298:2371-2380.
46. Henry T.D., Sharkey S.W., Burke M.N., et al. A regional system to provide timely access to percutaneous coronary intervention for ST-elevation myocardial infarction. Circulation 2007, 116:721-728.
47. Aguirre F.V., Varghese J.J., Kelley M.P., et al. Rural interhospital transfer of ST-elevation myocardial infarction patients for percutaneous coronary revascularization: the Stat Heart Program. Circulation 2008, 117:1145-1152.
48. Blankenship J.C., Scott T.D., Skelding K.A., et al. Door-to-balloon times under 90 min can be routinely achieved for patients transferred for ST-segment elevation myocardial infarction percutaneous coronary intervention in a rural setting. J Am Coll Cardiol 2011, 57:272-279.
49. Armstrong P.W., Boden W.E. Reperfusion paradox in ST-segment elevation myocardial infarction. Ann Intern Med 2011, 155:389-391.
50. Henry T.D., Gibson C.M., Pinto D.S. Moving toward improved care for the patient with ST-elevation myocardial infarction: a mandate for systems of care. Circ Cardiovasc Qual Outcomes 2010, 3:441-443.
51. Indications for fibrinolytic therapy in suspected acute myocardial infarction: collaborative overview of early mortality and major morbidity results from all randomised trials of more than 1000 patients. Fibrinolytic therapy trialists' (FTT) collaborative group. Lancet 1994, 343:311-322.
52. Boersma E., Maas A.C., Deckers J.W., et al. Early thrombolytic treatment in acute myocardial infarction: reappraisal of the golden hour. Lancet 1996, 348:771-775.
53. An international randomized trial comparing four thrombolytic strategies for acute myocardial infarction. The GUSTO investigators. N Engl J Med 1993, 329:673-682.
54. A comparison of reteplase with alteplase for acute myocardial infarction. The global use of strategies to open occluded coronary arteries (GUSTO III) investigators. N Engl J Med 1997, 337:1118-1123.
55. Van De Werf F., Adgey J., Ardissino D., et al. Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 1999, 354:716-722. Assessment of the Safety and Efficacy of a New Thrombolytic (ASSENT-2) Investigators.
56. Gershlick A.H., Stephens-Lloyd A., Hughes S., et al. Rescue angioplasty after failed thrombolytic therapy for acute myocardial infarction. N Engl J Med 2005, 353:2758-2768.
57. Carver A., Rafelt S., Gershlick A.H., et al. Longer-term follow-up of patients recruited to the REACT (rescue angioplasty versus conservative treatment or repeat thrombolysis) trial. J Am Coll Cardiol 2009, 54:118-126.
58. Keeley E.C., Boura J.A., Grines C.L. Comparison of primary and facilitated percutaneous coronary interventions for ST-elevation myocardial infarction: quantitative review of randomised trials. Lancet 2006, 367:579-588.
59. Baron S.J., Giugliano R.P. Effectiveness and safety of percutaneous coronary intervention after fibrinolytic therapy for ST-segment elevation acute myocardial infarction. Am J Cardiol 2011, 107:1001-1009.
60. Fernandez-Avilés F., Alonso J.J., Castro-Beiras A., et al. Routine invasive strategy within 24 hours of thrombolysis versus ischaemia-guided conservative approach for acute myocardial infarction with ST-segment elevation (GRACIA-1): a randomised controlled trial. Lancet 2004, 364:1045-1053.
61. Bøhmer E., Hoffmann P., Abdelnoor M., et al. Efficacy and safety of immediate angioplasty versus ischemia-guided management after thrombolysis in acute myocardial infarction in areas with very long transfer distances results of the NORDISTEMI (Norwegian study on DIstrict treatment of ST-elevation myocardial infarction). J Am Coll Cardiol 2010, 55:102-110.
62. Cantor W.J., Fitchett D., Borgundvaag B., et al. Routine early angioplasty after fibrinolysis for acute myocardial infarction. N Engl J Med 2009, 360:2705-2718.
63. Fernández-Avilés F., Alonso J.J., Peña G., et al. Primary angioplasty vs. early routine post-fibrinolysis angioplasty for acute myocardial infarction with ST-segment elevation: the GRACIA-2 non-inferiority, randomized, controlled trial. Eur Heart J 2007, 28:949-960.
64. Scheller B., Hennen B., Hammer B., et al. Beneficial effects of immediate stenting after thrombolysis in acute myocardial infarction. J Am Coll Cardiol 2003, 42:634-641.
65. Di Mario C., Dudek D., Piscione F., et al. Immediate angioplasty versus standard therapy with rescue angioplasty after thrombolysis in the combined abciximab reteplase Stent study in acute myocardial infarction (CARESS-in-AMI): an open, prospective, randomised, multicentre trial. Lancet 2008, 371:559-568.
66. A comparison of pharmacologic therapy with/without timely coronary intervention vs. primary percutaneous intervention early after ST-elevation myocardial infarction: the WEST (which early ST-elevation myocardial infarction therapy) study. Eur Heart J 2006, 27:1530-1538. Armstrong PW, WEST Steering Committee.
67. Pinto D.S., Frederick P.D., Chakrabarti A.K., et al. Benefit of transferring ST-Segment-Elevation myocardial infarction patients for percutaneous coronary intervention compared with administration of onsite fibrinolytic declines as delays increase. Circulation 2011, 124:2512-2521.
68. Eagle K.A., Goodman S.G., Avezum A., et al. Practice variation and missed opportunities for reperfusion in ST-segment-elevation myocardial infarction: findings from the Global Registry of Acute Coronary Events (GRACE). Lancet 2002, 359:373-377.
69. Schomig A., Mehilli J., Antoniucci D., et al. Mechanical reperfusion in patients with acute myocardial infarction presenting more than 12 hours from symptom onset: a randomized controlled trial. JAMA 2005, 293:2865-2872.
70. Gierlotka M., Gasior M., Wilczek K., et al. Reperfusion by primary percutaneous coronary intervention in patients with ST-segment elevation myocardial infarction within 12 to 24 hours of the onset of symptoms (from a prospective national observational study [PL-ACS]). Am J Cardiol 2011, 107:501-508.
71. Goldberg R.J., Spencer F.A., Gore J.M., et al. Thirty-year trends (1975 to 2005) in the magnitude of, management of, and hospital death rates associated with cardiogenic shock in patients with acute myocardial infarction: a population-based perspective. Circulation 2009, 119:1211-1219.
72. Hochman J.S., Sleeper L.A., Webb J.G., et al. Early revascularization in acute myocardial infarction complicated by cardiogenic shock. SHOCK investigators. Should we emergently revascularize occluded coronaries for cardiogenic shock. N Engl J Med 1999, 341:625-634.
73. Lee M.S., Bokhoor P., Park S.J., et al. Unprotected left main coronary disease and ST-segment elevation myocardial infarction: a contemporary review and argument for percutaneous coronary intervention. JACC Cardiovasc Intv 2010, 3:791-795.
74. Sorajja P., Gersh B.J., Cox D.A., et al. Impact of multivessel disease on reperfusion success and clinical outcomes in patients undergoing primary percutaneous coronary intervention for acute myocardial infarction. Eur Heart J 2007, 28:1709-1716.
75. Vlaar P.J., Mahmoud K.D., Holmes D.R., et al. Culprit vessel only versus multivessel and staged percutaneous coronary intervention for multivessel disease in patients presenting with ST-segment elevation myocardial infarction: a pairwise and network meta-analysis. J Am Coll Cardiol 2011, 58:692-703.
76. Kornowski R., Mehran R., Dangas G., et al. Prognostic impact of staged versus "one-time" multivessel percutaneous intervention in acute myocardial infarction: analysis from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2011, 58:704-711.
77. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Addition of clopidogrel to aspirin and fibrinolytic therapy for myocardial infarction with ST-segment elevation. N Engl J Med 2005, 352:1179-1189.
78. Chen Z.M., Jiang L.X., Chen Y.P., et al. Addition of clopidogrel to aspirin in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1607-1621.
79. Sabatine M.S., Cannon C.P., Gibson C.M., et al. Effect of clopidogrel pretreatment before percutaneous coronary intervention in patients with ST-elevation myocardial infarction treated with fibrinolytics: the PCI-CLARITY study. JAMA 2005, 294:1224-1232.
80. Mehta S.R., Yusuf S., Peters R.J., et al. Effects of pretreatment with clopidogrel and aspirin followed by long-term therapy in patients undergoing percutaneous coronary intervention: the PCI-CURE study. Lancet 2001, 358:527-533.
81. Steinhubl S.R., Berger P.B., Mann J.T., et al. Early and sustained dual oral antiplatelet therapy following percutaneous coronary intervention: a randomized controlled trial. JAMA 2002, 288:2411-2420.
82. Reinhart K.M., White C.M., Baker W.L. Prasugrel: a critical comparison with clopidogrel. Pharmacotherapy 2009, 29:1441-1451.
83. Dangas G., Mehran R., Guagliumi G., et al. Role of clopidogrel loading dose in patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: results from the HORIZONS-AMI (harmonizing outcomes with revascularization and stents in acute myocardial infarction) trial. J Am Coll Cardiol 2009, 54:1438-1446.
84. Mehta S.R., Bassand J.P., Chrolavicius S., et al. Dose comparisons of clopidogrel and aspirin in acute coronary syndromes. N Engl J Med 2010, 363:930-942. CURRENT-OASIS 7 Investigators.
85. Patti G., Bárczi G., Orlic D., et al. Outcome comparison of 600- and 300-mg loading doses of clopidogrel in patients undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: results from the ARMYDA-6 MI (antiplatelet therapy for reduction of myocardial damage during angioplasty-myocardial infarction) randomized study. J Am Coll Cardiol 2011, 58:1592-1599.
86. Mega J.L., Close S.L., Wiviott S.D., et al. Cytochrome p-450 polymorphisms and response to clopidogrel. N Engl J Med 2009, 360:354-362.
87. Breet N.J., van Werkum J.W., Bouman H.J., et al. Comparison of platelet function tests in predicting clinical outcome in patients undergoing coronary stent implantation. JAMA 2010, 303:754-762.
88. Holmes D.R., Dehmer G.J., Kaul S., et al. ACCF/AHA clopidogrel clinical alert: approaches to the FDA "boxed warning": a report of the American College of Cardiology Foundation Task Force on Clinical expert consensus documents and the American Heart Association endorsed by the society for cardiovascular angiography and Interventions and the Society of Thoracic Surgeons. J Am Coll Cardiol 2010, 56:321-341.
89. Wiviott S.D., Braunwald E., McCabe C.H., et al. Prasugrel versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2007, 357:2001-2015.
90. Gurbel P.A., Bliden K.P., Butler K., et al. Randomized double-blind assessment of the ONSET and OFFSET of the antiplatelet effects of ticagrelor versus clopidogrel in patients with stable coronary artery disease: the ONSET/OFFSET study. Circulation 2009, 120:2577-2585.
91. Wallentin L., Becker R.C., Budaj A., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes. N Engl J Med 2009, 361:1045-1057.
92. Steg P.G., James S., Harrington R.A., et al. Ticagrelor versus clopidogrel in patients with ST-elevation acute coronary syndromes intended for reperfusion with primary percutaneous coronary intervention: A platelet inhibition and patient outcomes (PLATO) trial subgroup analysis. Circulation 2010, 122:2131-2141.
93. James S.K., Roe M.T., Cannon C.P., et al. Ticagrelor versus clopidogrel in patients with acute coronary syndromes intended for non-invasive management: substudy from prospective randomised PLATelet inhibition and patient outcomes (PLATO) trial. BMJ 2011, 342:d3527.
94. Mahaffey K.W., Wojdyla D.M., Carroll K., et al. Ticagrelor compared with clopidogrel by geographic region in the platelet inhibition and patient outcomes (PLATO) trial. Circulation 2011, 124:544-554.
95. Coulter S.A., Cannon C.P., Ault K.A., et al. High levels of platelet inhibition with abciximab despite heightened platelet activation and aggregation during thrombolysis for acute myocardial infarction: results from TIMI (thrombolysis in myocardial infarction) 14. Circulation 2000, 101:2690-2695.
96. De Luca G., Suryapranata H., Stone G.W., et al. Abciximab as adjunctive therapy to reperfusion in acute ST-segment elevation myocardial infarction: a meta-analysis of randomized trials. JAMA 2005, 293:1759-1765.
97. Cohen M., Gensini G.F., Maritz F., et al. The safety and efficacy of subcutaneous enoxaparin versus intravenous unfractionated heparin and tirofiban versus placebo in the treatment of acute ST-segment elevation myocardial infarction patients ineligible for reperfusion (TETAMI): a randomized trial. J Am Coll Cardiol 2003, 42:1348-1356.
98. Neumann F.J., Blasini R., Schmitt C., et al. Effect of glycoprotein IIb/IIIa receptor blockade on recovery of coronary flow and left ventricular function after the placement of coronary-artery stents in acute myocardial infarction. Circulation 1998, 98:2695-2701.
99. Valgimigli M., Campo G., Percoco G., et al. Comparison of angioplasty with infusion of tirofiban or abciximab and with implantation of sirolimus-eluting or uncoated stents for acute myocardial infarction: the multistrategy randomized trial. JAMA 2008, 299:1788-1799.
100. Akerblom A., James S.K., Koutouzis M., et al. Eptifibatide is noninferior to abciximab in primary percutaneous coronary intervention: results from the SCAAR (Swedish coronary angiography and angioplasty registry). J Am Coll Cardiol 2010, 56:470-475.
101. Ellis S.G., Tendera M., de Belder M.A., et al. Facilitated PCI in patients with ST-elevation myocardial infarction. N Engl J Med 2008, 358:2205-2217.
102. ten Berg J.M., van 't Hof A.W., Dill T., et al. Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome. J Am Coll Cardiol 2010, 55:2446-2455.
103. Eisenberg P.R., Sobel B.E., Jaffe A.S. Activation of prothrombin accompanying thrombolysis with recombinant tissue-type plasminogen activator. J Am Coll Cardiol 1992, 19:1065-1069.
104. de Bono D.P., Simoons M.L., Tijssen J., et al. Effect of early intravenous heparin on coronary patency, infarct size, and bleeding complications after alteplase thrombolysis: results of a randomised double blind European Cooperative Study Group trial. Br Heart J 1992, 67:122-128.
105. Eikelboom J.W., Quinlan D.J., Mehta S.R., et al. Unfractionated and low-molecular-weight heparin as adjuncts to thrombolysis in aspirin-treated patients with ST-elevation acute myocardial infarction: a meta-analysis of the randomized trials. Circulation 2005, 112:3855-3867.
106. Brener S.J., Moliterno D.J., Lincoff A.M., et al. Relationship between activated clotting time and ischemic or hemorrhagic complications: analysis of 4 recent randomized clinical trials of percutaneous coronary intervention. Circulation 2004, 110:994-998.
107. Yusuf S., Mehta S.R., Xie C., et al. Effects of reviparin, a low-molecular-weight heparin, on mortality, reinfarction, and strokes in patients with acute myocardial infarction presenting with ST-segment elevation. JAMA 2005, 293:427-435.
108. Antman E.M., Morrow D.A., McCabe C.H., et al. Enoxaparin versus unfractionated heparin with fibrinolysis for ST-elevation myocardial infarction. N Engl J Med 2006, 354:1477-1488.
109. Murphy S.A., Gibson C.M., Morrow D.A., et al. Efficacy and safety of the low-molecular weight heparin enoxaparin compared with unfractionated heparin across the acute coronary syndrome spectrum: a meta-analysis. Eur Heart J 2007, 28:2077-2086.
110. Gibson C.M., Murphy S.A., Montalescot G., et al. Percutaneous coronary intervention in patients receiving enoxaparin or unfractionated heparin after fibrinolytic therapy for ST-segment elevation myocardial infarction in the ExTRACT-TIMI 25 trial. J Am Coll Cardiol 2007, 49:2238-2246.
111. Montalescot G., Zeymer U., Silvain J., et al. Intravenous enoxaparin or unfractionated heparin in primary percutaneous coronary intervention for ST-elevation myocardial infarction: the international randomised open-label ATOLL trial. Lancet 2011, 378:693-703.
112. White H. Hirulog and Early Reperfusion or Occlusion (HERO)-2 Trial Investigators. Thrombin-specific anticoagulation with bivalirudin versus heparin in patients receiving fibrinolytic therapy for acute myocardial infarction: the hero-2 randomised trial. Lancet 2001, 358:1855-1863.
113. Stone G.W., Witzenbichler B., Guagliumi G., et al. Bivalirudin during primary PCI in acute myocardial infarction. N Engl J Med 2008, 358:2218-2230.
114. Stone G.W., Witzenbichler B., Guagliumi G., et al. Heparin plus a glycoprotein IIb/IIIa inhibitor versus bivalirudin monotherapy and paclitaxel-eluting stents versus bare-metal stents in acute myocardial infarction (HORIZONS-AMI): final 3-year results from a multicentre, randomised controlled trial. Lancet 2011, 377:2193-2204.
115. Yusuf S., Mehta S.R., Chrolavicius S., et al. Effects of fondaparinux on mortality and reinfarction in patients with acute ST-segment elevation myocardial infarction: the oasis-6 randomized trial. JAMA 2006, 295:1519-1530.
116. Lau J., Antman E.M., Jimenez-Silva J., et al. Cumulative meta-analysis of therapeutic trials for myocardial infarction. N Engl J Med 1992, 327:248-254.
117. Freemantle N., Cleland J., Young P., et al. Beta blockade after myocardial infarction: systematic review and meta regression analysis. BMJ 1999, 318:1730-1737.
118. Roberts R., Rogers W.J., Mueller H.S., et al. Immediate versus deferred beta-blockade following thrombolytic therapy in patients with acute myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) II-B study. Circulation 1991, 83:422-437.
119. Chen Z.M., Pan H.C., Chen Y.P., et al. Early intravenous then oral metoprolol in 45,852 patients with acute myocardial infarction: randomised placebo-controlled trial. Lancet 2005, 366:1622-1632.
120. Halkin A., Grines C.L., Cox D.A., et al. Impact of intravenous beta-blockade before primary angioplasty on survival in patients undergoing mechanical reperfusion therapy for acute myocardial infarction. J Am Coll Cardiol 2004, 43:1780-1787.
121. Kernis S.J., Harjai K.J., Stone G.W., et al. Does beta-blocker therapy improve clinical outcomes of acute myocardial infarction after successful primary angioplasty?. J Am Coll Cardiol 2004, 43:1773-1779.
122. Smith S.C., Benjamin E.J., Bonow R.O., et al. AHA/ACCF secondary prevention and risk reduction therapy for patients with coronary and other atherosclerotic vascular disease: 2011 update: A guideline from the American Heart Association and American College of Cardiology Foundation. Circulation 2011, 124:2458-2473.
123. Ray K.K., Cannon C.P. The potential relevance of the multiple lipid-independent (pleiotropic) effects of statins in the management of acute coronary syndromes. J Am Coll Cardiol 2005, 46:1425-1433.
124. Baigent C., Blackwell L., Emberson J., et al. Efficacy and safety of more intensive lowering of LDL cholesterol: a meta-analysis of data from 170,000 participants in 26 randomised trials. Lancet 2010, 376:1670-1681. Cholesterol Treatment Trialists' (CTT) Collaboration.
125. Cannon C.P., Braunwald E., McCabe C.H., et al. Intensive versus moderate lipid lowering with statins after acute coronary syndromes. N Engl J Med 2004, 350:1495-1504.
126. Schwartz G.G., Olsson A.G., Ezekowitz M.D., et al. Effects of atorvastatin on early recurrent ischemic events in acute coronary syndromes: the MIRACL study: a randomized controlled trial. JAMA 2001, 285:1711-1718.
127. Patti G., Pasceri V., Colonna G., et al. Atorvastatin pretreatment improves outcomes in patients with acute coronary syndromes undergoing early percutaneous coronary intervention: results of the ARMYDA-ACS randomized trial. J Am Coll Cardiol 2007, 49:1272-1278.
128. Pfeffer M.A., Greaves S.C., Arnold J.M., et al. Early versus delayed angiotensin-converting enzyme inhibition therapy in acute myocardial infarction. The healing and early afterload reducing therapy trial. Circulation 1997, 95:2643-2651.
129. ISIS-4: a randomised factorial trial assessing early oral captopril, oral mononitrate, and intravenous magnesium sulphate in 58,050 patients with suspected acute myocardial infarction. ISIS-4 (Fourth International Study of Infarct Survival) Collaborative Group. Lancet 1995, 345:669-685.
130. Six-month effects of early treatment with lisinopril and transdermal glyceryl trinitrate singly and together withdrawn six weeks after acute myocardial infarction: the GISSI-3 trial. Gruppo Italiano per lo studio della Sopravvivenza nell'Infarto Miocardico. J Am Coll Cardiol 1996, 27:337-344.
131. Zuanetti G., Latini R., Maggioni A.P., et al. Effect of the ACE inhibitor lisinopril on mortality in diabetic patients with acute myocardial infarction: data from the GISSI-3 study. Circulation 1997, 96:4239-4245.
132. Pfeffer M.A., Braunwald E., Moyé L.A., et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction. Results of the survival and ventricular enlargement trial. The SAVE investigators. N Engl J Med 1992, 327:669-677.
133. Køber L., Torp-Pedersen C., Carlsen J.E., et al. A clinical trial of the angiotensin-converting-enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction. Trandolapril cardiac evaluation (TRACE) study group. N Engl J Med 1995, 333:1670-1676.
134. Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure. The acute infarction ramipril efficacy (AIRE) study investigators. Lancet 1993, 342:821-828.
135. Swedberg K., Held P., Kjekshus J., et al. Effects of the early administration of enalapril on mortality in patients with acute myocardial infarction. Results of the cooperative new Scandinavian enalapril survival study II (CONSENSUS II). N Engl J Med 1992, 327:678-684.
136. Oral captopril versus placebo among 13,634 patients with suspected acute myocardial infarction: interim report from the Chinese cardiac study (CCS-1). Lancet 1995, 345:686-687.
137. Ambrosioni E., Borghi C., Magnani B. The effect of the angiotensin-converting-enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. The survival of myocardial infarction Long-term evaluation (SMILE) study investigators. N Engl J Med 1995, 332:80-85.
138. Dickstein K. Effects of losartan and captopril on mortality and morbidity in high-risk patients after acute myocardial infarction: the OPTIMAAL randomised trial. Optimal trial in myocardial infarction with angiotensin II antagonist losartan. Lancet 2002, 360:752-760. Kjekshus J, OPTIMAAL Steering Committee of the OPTIMAAL Study Group.
139. Pfeffer M.A., McMurray J.J., Velazquez E.J., et al. Valsartan, captopril, or both in myocardial infarction complicated by heart failure, left ventricular dysfunction, or both. N Engl J Med 2003, 349:1893-1906.
140. Finfer S., Chittock D.R., Su S.Y., et al. Intensive versus conventional glucose control in critically ill patients. N Engl J Med 2009, 360:1283-1297. NICE-SUGAR Study Investigators.
141. Brook R.D., Rajagopalan S., Pope C.A., et al. Particulate matter air pollution and cardiovascular disease: an update to the scientific statement from the American Heart Association. Circulation 2010, 121:2331-2378.
142. Gersh B.J., Sliwa K., Mayosi B.M., et al. Novel therapeutic concepts: the epidemic of cardiovascular disease in the developing world: global implications. Eur Heart J 2010, 31:642-648.
143. Thombs B.D., Bass E.B., Ford D.E., et al. Prevalence of depression in survivors of acute myocardial infarction. J Gen Intern Med 2006, 21:30-38.
144. Ariyo A.A., Haan M., Tangen C.M., et al. Depressive symptoms and risks of coronary heart disease and mortality in elderly Americans. Cardiovascular Health Study Collaborative Research Group. Circulation 2000, 102:1773-1779.
145. Wassertheil-Smoller S., Shumaker S., Ockene J., et al. Depression and cardiovascular sequelae in postmenopausal women. The Women's Health Initiative (WHI). Arch Intern Med 2004, 164:289-298.
146. Thombs B.D., de Jonge P., Coyne J.C., et al. Depression screening and patient outcomes in cardiovascular care: a systematic review. JAMA 2008, 300:2161-2171.
147. Lichtman J.H., Bigger J.T., Blumenthal J.A., et al. Depression and coronary heart disease: recommendations for screening, referral, and treatment: a science advisory from the American Heart Association Prevention Committee of the Council on Cardiovascular Nursing, council on clinical cardiology, council on epidemiology and Prevention, and Interdisciplinary Council on Quality of Care and Outcomes Research: endorsed by the American Psychiatric Association. Circulation 2008, 118:1768-1775.
148. Jolliffe J.A., Rees K., Taylor R.S., et al. Exercise-based rehabilitation for coronary heart disease. Cochrane Database Syst Rev 2001, CD001800.
149. Suaya J.A., Stason W.B., Ades P.A., et al. Cardiac rehabilitation and survival in older coronary patients. J Am Coll Cardiol 2009, 54:25-33.
150. Goel K., Lennon R.J., Tilbury R.T., et al. Impact of cardiac rehabilitation on mortality and cardiovascular events after percutaneous coronary intervention in the community. Circulation 2011, 123:2344-2352.
151. Abraham N.S., Hlatky M.A., Antman E.M., et al. ACCF/ACG/AHA 2010 expert consensus document on the concomitant use of proton pump inhibitors and thienopyridines: a focused update of the ACCF/ACG/AHA 2008 expert consensus document on reducing the gastrointestinal risks of antiplatelet therapy and NSAID use. A report of the American College of Cardiology Foundation Task Force on expert consensus documents. J Am Coll Cardiol 2010, 56:2051-2066.
152. Bates E.R., Lau W.C., Angiolillo D.J. Clopidogrel-drug interactions. J Am Coll Cardiol 2011, 57:1251-1263.
153. Sørensen R., Hansen M.L., Abildstrom S.Z., et al. Risk of bleeding in patients with acute myocardial infarction treated with different combinations of aspirin, clopidogrel, and vitamin K antagonists in Denmark: a retrospective analysis of nationwide registry data. Lancet 2009, 374:1967-1974.
154. Hansen M.L., Sørensen R., Clausen M.T., et al. Risk of bleeding with single, dual, or triple therapy with warfarin, aspirin, and clopidogrel in patients with atrial fibrillation. Arch Intern Med 2010, 170:1433-1441.
155. Pitt B., Remme W., Zannad F., et al. Eplerenone, a selective aldosterone blocker, in patients with left ventricular dysfunction after myocardial infarction. N Engl J Med 2003, 348:1309-1321.
156. Hohnloser S.H., Kuck K.H., Dorian P., et al. Prophylactic use of an implantable cardioverter-defibrillator after acute myocardial infarction. N Engl J Med 2004, 351:2481-2488.
157. Steinbeck G., Andresen D., Seidl K., et al. Defibrillator implantation early after myocardial infarction. N Engl J Med 2009, 361:1427-1436.
158. Epstein A.E., DiMarco J.P., Ellenbogen K.A., et al. ACC/AHA/HRS Guidelines for device-based therapy of cardiac rhythm abnormalities: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines (Writing Committee to revise the ACC/AHA/NASPE 2002 guideline update for implantation of cardiac pacemakers and antiarrhythmia devices): developed in collaboration with the American Association for Thoracic Surgery and society of thoracic surgeons. Circulation 2008, 117:e350-e408.
159. Antman E.M., Cohen M., Bernink P.J., et al. The TIMI risk score for unstable angina/non-ST elevation MI: A method for prognostication and therapeutic decision making. JAMA 2000, 284:835-842.
160. Granger C.B., Goldberg R.J., Dabbous O., et al. Predictors of hospital mortality in the global registry of acute coronary events. Arch Intern Med 2003, 163:2345-2353.
161. Sanchis J., Bodí V., Núñez J., et al. New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations: a comparison with the TIMI risk score. J Am Coll Cardiol 2005, 46:443-449.
162. Eagle K.A., Lim M.J., Dabbous O.H., et al. A validated prediction model for all forms of acute coronary syndrome: estimating the risk of 6-month postdischarge death in an international registry. JAMA 2004, 291:2727-2733.
163. de Araujo Goncalves P., Ferreira J., Aguiar C., et al. TIMI, PURSUIT, and GRACE risk scores: sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005, 26:865-872.
164. Fox K.A., Dabbous O.H., Goldberg R.J., et al. Prediction of risk of death and myocardial infarction in the six months after presentation with acute coronary syndrome: prospective multinational observational study (GRACE). BMJ 2006, 333:1091.
165. Yusuf S., Zhao F., Mehta S.R., et al. Effects of clopidogrel in addition to aspirin in patients with acute coronary syndromes without ST-segment elevation. N Engl J Med 2001, 345:494-502.
166. Yusuf S., Mehta S.R., Zhao F., et al. Early and late effects of clopidogrel in patients with acute coronary syndromes. Circulation 2003, 107:966-972.
167. Boersma E., Harrington R.A., Moliterno D.J., et al. Platelet glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: a meta-analysis of all major randomised clinical trials. Lancet 2002, 359:189-198.
168. Simoons M.L. GUSTO IV-ACS Investigators. Effect of glycoprotein IIb/IIIa receptor blocker abciximab on outcome in patients with acute coronary syndromes without early coronary revascularisation: the GUSTO IV-ACS randomised trial. Lancet 2001, 357:1915-1924.
169. Kastrati A., Mehilli J., Neumann F.J., et al. Abciximab in patients with acute coronary syndromes undergoing percutaneous coronary intervention after clopidogrel pretreatment: the ISAR-REACT 2 randomized trial. JAMA 2006, 295:1531-1538.
170. Stone G.W., Bertrand M.E., Moses J.W., et al. Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA 2007, 297:591-602.
171. Giugliano R.P., White J.A., Bode C., et al. Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 2009, 360:2176-2190.
172. Eikelboom J.W., Anand S.S., Malmberg K., et al. Unfractionated heparin and low-molecular-weight heparin in acute coronary syndrome without ST elevation: a meta-analysis. Lancet 2000, 355:1936-1942.
173. Cohen M., Demers C., Gurfinkel E.P., et al. A comparison of low-molecular-weight heparin with unfractionated heparin for unstable coronary artery disease. Efficacy and safety of subcutaneous enoxaparin in non-Q-Wave Coronary Events Study Group. N Engl J Med 1997, 337:447-452.
174. Antman E.M., McCabe C.H., Gurfinkel E.P., et al. Enoxaparin prevents death and cardiac ischemic events in unstable angina/non-Q-wave myocardial infarction. Results of the thrombolysis in myocardial infarction (TIMI) 11B trial. Circulation 1999, 100:1593-1601.
175. Blazing M.A., de Lemos J.A., White H.D., et al. Safety and efficacy of enoxaparin vs unfractionated heparin in patients with non-ST-segment elevation acute coronary syndromes who receive tirofiban and aspirin: a randomized controlled trial. JAMA 2004, 292:55-64.
176. Ferguson J.J., Califf R.M., Antman E.M., et al. Enoxaparin vs unfractionated heparin in high-risk patients with non-ST-segment elevation acute coronary syndromes managed with an intended early invasive strategy: primary results of the SYNERGY randomized trial. JAMA 2004, 292:45-54.
177. Petersen J.L., Mahaffey K.W., Hasselblad V., et al. Efficacy and bleeding complications among patients randomized to enoxaparin or unfractionated heparin for antithrombin therapy in non-ST-Segment elevation acute coronary syndromes: a systematic overview. JAMA 2004, 292:89-96.
178. Stone G.W., McLaurin B.T., Cox D.A., et al. Bivalirudin for patients with acute coronary syndromes. N Engl J Med 2006, 355:2203-2216.
179. Yusuf S., Mehta S.R., Chrolavicius S.R., et al. Comparison of fondaparinux and enoxaparin in acute coronary syndromes. N Engl J Med 2006, 354:1464-1476. Fifth Organization to Assess Strategies in Acute Ischemic Syndromes Investigators.
180. Effects of tissue plasminogen activator and a comparison of early invasive and conservative strategies in unstable angina and non-Q-wave myocardial infarction.Results of the TIMI IIIB trial. Thrombolysis in myocardial ischemia. Circulation 1994, 89:1545-1556.
181. Invasive compared with non-invasive treatment in unstable coronary-artery disease: FRISC II prospective randomised multicentre study. Fragmin and fast revascularisation during InStability in coronary artery disease investigators. Lancet 1999, 354:708-715.
182. Cannon C.P., Weintraub W.S., Demopoulos L.A., et al. Comparison of early invasive and conservative strategies in patients with unstable coronary syndromes treated with the glycoprotein IIb/IIIa inhibitor tirofiban. N Engl J Med 2001, 344:1879-1887.
183. Fox K.A., Poole-Wilson P.A., Henderson R.A., et al. Interventional versus conservative treatment for patients with unstable angina or non-ST-elevation myocardial infarction. British Heart Foundation RITA randomised trial. Randomized Intervention Trial of Unstable Angina. Lancet 2002, 360:743-751.
184. de Winter R.J., Windhausen F., Cornel J.H., et al. Early invasive versus selectively invasive management for acute coronary syndromes. N Engl J Med 2005, 353:1095-1104.
185. Bavry A.A., Kumbhani D.J., Rassi A.N., et al. Benefit of early invasive therapy in acute coronary syndromes: a meta-analysis of contemporary randomized clinical trials. J Am Coll Cardiol 2006, 48:1319-1325.
186. Fox K.A., Clayton T.C., Damman P., et al. Long-term outcome of a routine versus selective invasive strategy in patients with non-ST-segment elevation acute coronary syndrome a meta-analysis of individual patient data. J Am Coll Cardiol 2010, 55:2435-2445.
187. Mehta S.R., Granger C.B., Boden W.E., et al. Early versus delayed invasive intervention in acute coronary syndromes. N Engl J Med 2009, 360:2165-2175.
188. Montalescot G., Cayla G., Collet J.P., et al. Immediate vs delayed intervention for acute coronary syndromes: a randomized clinical trial. JAMA 2009, 302:947-954.
189. Szummer K., Lundman P., Jacobson S.H., et al. Influence of renal function on the effects of early revascularization in non-ST-elevation myocardial infarction: data from the Swedish Web-system for enhancement and development of evidence-based care in Heart Disease evaluated According to recommended therapies (SWEDEHEART). Circulation 2009, 120:851-858.
190. Lavie C.J., Gersh B.J. Mechanical and electrical complications of acute myocardial infarction. Mayo Clin Proc Mayo Clin 1990, 65:709-730.
191. Kishon Y., Oh J.K., Schaff H.V., et al. Mitral valve operation in postinfarction rupture of a papillary muscle: immediate results and long-term follow-up of 22 patients. Mayo Clin Proc Mayo Clin 1992, 67:1023-1030.
192. Figueras J., Alcalde O., Barrabés J.A., et al. Changes in hospital mortality rates in 425 patients with acute ST-elevation myocardial infarction and cardiac rupture over a 30-year period. Circulation 2008, 118:2783-2789.
193. Becker R.C., Gore J.M., Lambrew C., et al. A composite view of cardiac rupture in the united states national registry of myocardial infarction. J Am Coll Cardiol 1996, 27:1321-1326.
194. Becker R.C., Hochman J.S., Cannon C.P., et al. Fatal cardiac rupture among patients treated with thrombolytic agents and adjunctive thrombin antagonists: observations from the thrombolysis and thrombin inhibition in myocardial infarction 9 study. J Am Coll Cardiol 1999, 33:479-487.
195. Pohjola-Sintonen S., Muller J.E., Stone P.H., et al. Ventricular septal and free wall rupture complicating acute myocardial infarction: experience in the multicenter investigation of limitation of infarct size. Am Heart J 1989, 117:809-818.
196. Oliva P.B., Hammill S.C., Edwards W.D. Cardiac rupture, a clinically predictable complication of acute myocardial infarction: report of 70 cases with clinicopathologic correlations. J Am Coll Cardiol 1993, 22:720-726.
197. López-Sendón J., González A., López de Sá E., et al. Diagnosis of subacute ventricular wall rupture after acute myocardial infarction: sensitivity and specificity of clinical, hemodynamic and echocardiographic criteria. J Am Coll Cardiol 1992, 19:1145-1153.
198. Crenshaw B.S., Granger C.B., Birnbaum Y., et al. Risk factors, angiographic patterns, and outcomes in patients with ventricular septal defect complicating acute myocardial infarction. GUSTO-I (global utilization of streptokinase and TPA for occluded coronary arteries) trial investigators. Circulation 2000, 101:27-32.
199. Jones M.T., Schofield P.M., Dark J.F., et al. Surgical repair of acquired ventricular septal defect. Determinants of early and late outcome. J Thorac Cardiovasc Surg 1987, 93:680-686.
200. Landzberg M.J., Lock J.E. Transcatheter management of ventricular septal rupture after myocardial infarction. Semin Thorac Cardiovasc Surg 1998, 10:128-132.
201. Archbold R.A., Sayer J.W., Ray S., et al. Frequency and prognostic implications of conduction defects in acute myocardial infarction since the introduction of thrombolytic therapy. Eur Heart J 1998, 19:893-898.
202. Aplin M., Engstrøm T., Vejlstrup N.G., et al. Prognostic importance of complete atrioventricular block complicating acute myocardial infarction. Am J Cardiol 2003, 92:853-856.
203. Wong C.K., Stewart R.A., Gao W., et al. Prognostic differences between different types of bundle branch block during the early phase of acute myocardial infarction: insights from the hirulog and early reperfusion or occlusion (HERO)-2 trial. Eur Heart J 2006, 27:21-28.
204. Schmitt J., Duray G., Gersh B.J., et al. Atrial fibrillation in acute myocardial infarction: a systematic review of the incidence, clinical features and prognostic implications. Eur Heart J 2009, 30:1038-1045.
205. Wong C.K., White H.D., Wilcox R.G., et al. New atrial fibrillation after acute myocardial infarction independently predicts death: the GUSTO-III experience. Am Heart J 2000, 140:878-885.
206. Lehto M., Snapinn S., Dickstein K., et al. Prognostic risk of atrial fibrillation in acute myocardial infarction complicated by left ventricular dysfunction: the OPTIMAAL experience. Eur Heart J 2005, 26:350-356.
207. Gorgels A.P., Vos M.A., Letsch I.S., et al. Usefulness of the accelerated idioventricular rhythm as a marker for myocardial necrosis and reperfusion during thrombolytic therapy in acute myocardial infarction. Am J Cardiol 1988, 61:231-235.
208. Scirica B.M., Braunwald E., Belardinelli L., et al. Relationship between nonsustained ventricular tachycardia after non-ST-elevation acute coronary syndrome and sudden cardiac death: observations from the metabolic efficiency with ranolazine for less ischemia in non-ST-elevation acute coronary syndrome-thrombolysis in myocardial infarction 36 (Merlin-TIMI 36) randomized controlled trial. Circulation 2010, 122:455-462.
209. Newby K.H., Thompson T., Stebbins A., et al. Sustained ventricular arrhythmias in patients receiving thrombolytic therapy: incidence and outcomes. The GUSTO investigators. Circulation 1998, 98:2567-2573.
210. Neumar R.W., Otto C.W., Link M.S., et al. Part 8: Adult advanced cardiovascular life support: 2010 American Heart Association Guidelines for Cardiopulmonary Resuscitation and Emergency Cardiovascular Care. Circulation 2010, 122:S729-S767.
211. Bagnall A.J., Yan A.T., Yan R.T., et al. Optimal medical therapy for non-ST-segment-elevation acute coronary syndromes: exploring why physicians do not prescribe evidence-based treatment and why patients discontinue medications after discharge. Circ Cardiovasc Qual Outcomes 2010, 3:530-537.